Similarly, despite the initial promising efficacy and safety of bintrafusp alfa, a bifunctional protein targeting TGF-β and PD-L1, it failed to provide benefits to ICI-naïve NSCLC patients with high PD-L1 expression compared to pembrolizumab in the phase III Lung-037 study. Here, CD274 is linked to non-small cell lung carcinoma.